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Failure to capture can result from several causes, including
battery depletion, circuit failure, lead dislodgement or
maturation, elevated capture thresholds due to progressive
cardiac disease, metabolic abnormalities and or drugs. We
present a unique case of intermittent failure to capture and
describe the mechanism.Case report
An 82-year-old Caucasian female patient, who had a history
of hypertension, dual-chamber pacer implantation for par-
oxysmal atrial ﬁbrillation, and sick sinus syndrome 3 years
ago, was transferred from an outside hospital for evaluation
and management of a wide complex tachycardia at 115
beats per minute (bpm). Her home medications included
candesartan-hydrochlorothiazide (32/12.5 mg daily), ﬂecai-
nide (100 mg twice daily), metoprolol tartrate (25 mg twice
daily), and amiodarone (200 mg daily). She was started on
doxycycline for left foot infection 4 days prior to the
admission, which resulted in nausea and multiple episodes
of vomiting. She was hemodynamically stable. Initial
laboratory test results were pertinent to acute kidney injury,
with serum bicarbonate level of 12 mmol/L (normal range
17–29 mmol/L), blood urea nitrogen level of 63 mg/dL
(normal range 8–23 mg/dL), and serum creatinine concen-
tration of 2.5 mg/dL (normal 0.5–1.0 mg/dL). Her presenting
electrocardiogram (ECG) showed a wide complex rhythm
with intermittent loss of ventricular capture (Figure 1A).
What is the mechanism of this intermittent failure to capture?
The initial ECG (Figure 1A) showed a very wide complex
tachycardia (QRS duration of 240 ms) at 115 bpm with
group beating due to intermittent failure to capture. An
examination of the lead V1 results demonstrated P waves
preceding every QRS complex, which was consistent with PKEYWORDS Pacemaker malfunction; Failure to capture; Flecainide; Over-
dose; Use-dependent block (Heart Rhythm Case Reports 2016;2:178–182)
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demonstrated on the intracardiac electrogram from the
pacing device (Figure 1B). Differential diagnoses included
sinus tachycardia or atrial tachycardia with ventricular
tracking. Interestingly, the width of the QRS complex
gradually increased such that the last QRS complex before
the pause was much wider than the ﬁrst QRS after the pause.
This phenomenon of rate-dependent or use-dependent wid-
ening of QRS complexes is classically seen with ﬂecainide
(class IC antiarrhythmic agent). The intermittent failure to
capture during ventricular pacing is the result of the pacing
stimulus occurring during the refractory period of the
previous beat, with a very delayed depolarization (Figures
1A and 1B). This phenomenon is referred to as functional
noncapture. These ECG ﬁndings in our patient in the setting
of acute kidney injury from intravascular volume depletion
(multiple episodes of vomiting, use of diuretic) and con-
current use of amiodarone strongly raised the suspicion for
ﬂecainide toxicity. Flecainide and amiodarone therapies
were discontinued. The pacing device was reprogrammed
from DDD mode to DDI mode at 70 bpm to avoid tracking
and to decrease the ventricular rate. The patient was
aggressively hydrated with intravenous ﬂuids. Anion gap
metabolic acidosis, in the setting of a very wide QRS, was
acutely treated with 100 milliequivalents of intravenous
sodium bicarbonate. Flecainide levels obtained at the time
of admission were elevated, at 1400 ng/mL (normal 200–
1000 ng/mL). After 48 hours of conservative management,
her acidosis and acute kidney injury resolved. The nonpaced
ECG before and after treatment demonstrated remarkable
narrowing of QRS complexes (Figures 2A and 2B).Discussion
Flecainide (class IC antiarrhythmic agent) is a potent sodium
channel blocker, which thereby decreases the slope of the
phase 0 depolarization (Vmax) and slows down the conduc-
tion velocity in cardiac tissue.1 It has negative inotropic
effects and therefore should be avoided in patients with
depressed ejection fraction.1 Furthermore, the use of ﬂecai-
nide is contraindicated in patients with myocardial infarc-
tion, because of excessive mortality risk as demonstrated
in the Cardiac Arrhythmia Suppression Trial (CAST).2
Flecainide can also increase pacing and deﬁbrillationpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Flecainide is a drug with a narrow therapeutic
index. A thorough understanding of the
pharmacokinetics and pharmacodynamics is
essential to prevent fatal overdose.
 The characteristic rate-dependent or use-
dependent effect property of ﬂecainide is due to its
high afﬁnity for open-state or inactivated sodium
channels and very slow unbinding kinetics.
 Widening of the QRS at rapid rates predisposes
patients to ventricular arrhythmias and can
potentially result in a loss of ventricular capture in
patients with pacemakers.
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without structural heart disease, for the prevention of
paroxysmal supraventricular tachycardias (atrioventricular
nodal reentry, atrioventricular reentry), paroxysmal atrial
ﬁbrillation/ﬂutter, and sustained life-threatening ventricular
tachycardia. Flecainide is also emerging as a novel strategy
in preventing ventricular arrhythmias in patients with cat-
echolaminergic polymorphic ventricular tachycardia, by
inhibiting the cardiac ryanodine receptors and thus prevent-
ing diastolic calcium overload.1 On oral administration,
ﬂecainide is extensively absorbed, with bioavailability reach-
ing 90%–95%. It undergoes negligible hepatic ﬁrst-pass
metabolism and is poorly bound to the plasma proteins. The
elimination half-life is 12–27 hours. It undergoes extensive
hepatic biotransformation via cytochrome P450 (CYP) 2D6
into two major metabolites. Flecainide and its metabolites are
excreted primarily (85%) in urine.3 Hence, the dose should
be adjusted in patients with renal or hepatic impairment.
Furthermore, drugs that inhibit CYP2D6 and decrease
hepatic metabolism can increase the plasma concentrations
of ﬂecainide by 2-fold or more.3 One such example is
amiodarone, which our patient was taking along with
ﬂecainide. In the present case, amiodarone was prescribed
by an outside physician, and its prescription was probably an
oversight. In one study, the mean percent increase in the
dose-adjusted plasma ﬂecainide levels after initiation of
amiodarone was 60%.4 The authors hypothesized that more
than one mechanism of interaction may be operative includ-
ing decreased rate of enzymatic biotransformation from
altered hepatic function, a decrease in renal elimination,
and/or a change in drug distribution.4
The electrocardiographic changes associated with ﬂecai-
nide ingestion include PR prolongation and widening of the
QRS interval, even at physiologic heart rates. Flecainide has
high afﬁnity for open-state and inactivated sodium channels
and exhibits very slow unbinding kinetics from these
channels. At faster heart rates, as the sodium channels spend
more time in an open or inactivated state, there is greater
binding of ﬂecainide to these channels. The shorteneddiastolic time for recovery from the block at rapid heart
rates coupled with the slow dissociation properties of
ﬂecainide from these channels further enhances sodium
channel blockade and the slowing of the conduction. This
phenomenon explains the characteristic property of ﬂecai-
nide referred to as “rate-dependent” or “use-dependent”
effect that occurs at rapid heart rates, resulting in profound
QRS widening that predisposes to ventricular proarrhyth-
mia.2 Additionally, rate-dependent widening of the QRS can
lead to functional noncapture, as was observed in our case,
that may have grave consequences in a pacemaker-
dependent patient. Exercise treadmill testing can be per-
formed to assess the use-dependent QRS widening in
patients who are treated with ﬂecainide. The risk factors
for ventricular proarrhythmia in patients taking ﬂecainide
include wide QRS (4120 milliseconds), depressed ejection
fraction, coronary artery disease, high heart rates, high dose
of Flecainide, hypokalemia, severe renal failure (creatinine
clearance r35 mL/min/1.73 m2), and excessive QRS
widening (4150% from baseline).1
Flecainide is considered to be a narrow therapeutic-index
drug, with steep dose-response relationships for the efﬁcacy,
toxicity or both in the usual dosing interval.5 The cardiovas-
cular adverse effects begin to rise at a plasma level of
approximately 750 ng/mL and reach 50% at 1500 ng/mL.5
Drug overdose with ﬂecainide is frequently fatal with
reported mortality rates as high as 10%.6 Toxicity presents
electrocardiographically as widening of the PR and QRS
intervals, and clinically as hypotension, bradycardia, atrio-
ventricular conduction block, premature ventricular ectopy,
ventricular tachycardia, and/or ventricular ﬁbrillation. The
treatment is support with aggressive ﬂuid resuscitation.
Flecainide should be promptly discontinued, and any electro-
lyte derangements should be corrected. There is no speciﬁc
antidote for ﬂecainide overdose. Hypertonic sodium bicar-
bonate has been shown to be effective in patients with wide
QRS, hypotension, and ventricular ectopy. Hypertonic
sodium bicarbonate competes with binding of ﬂecainide to
the sodium channels, thereby reversing the effect of ﬂecai-
nide on cardiac excitability and conduction.3 Intravenous
lipid emulsion as a novel adjunctive therapy has also been
shown to be effective in reversing the adverse cardiac effects
associated with ﬂecainide overdose. Intravenous lipid emul-
sion is hypothesized to function as a “lipid sink,” thus
recruiting and sequestering the lipophilic medications (eg,
ﬂecainide) from the receptor sites.7Conclusions
Flecainide is a narrow therapeutic-index drug, and drug
overdose can be fatal. The characteristic rate-dependent or
use-dependent effect property of ﬂecainide is due to high
afﬁnity for open-state or inactivated sodium channels and
very slow unbinding kinetics from these channels. Widening
of the QRS at rapid rates predisposes patients to ventricular
arrhythmias and can potentially result in a loss of ventricular
Figure 1 A: Baseline paced electrocardiogram. Electrocardiogram shows atrial sensed ventricular paced rhythm with a very wide complex tachycardia (QRS
duration of 240 milliseconds) at 115 beats per minute with group beating due to intermittent failure to capture. Note, the width of the QRS complex gradually
increases such that the last QRS complex before the pause is much wider than the ﬁrst QRS after the pause. B: Intracardiac electrogram. Atrial sensed ventricular
paced rhythm with intermittent failure to capture.
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Figure 2 A: Baseline nonpaced electrocardiogram shows atrial ﬁbrillation with a wide complex QRS measuring 200 milliseconds. B: Nonpaced
electrocardiogram recorded after 48 hours. The electrocardiogram shows atrial ﬁbrillation with QRS measuring 136 milliseconds.
181Padala et al Failure to Capturecapture in patients with pacemakers. Physicians prescribing
or managing patients on ﬂecainide should have thorough
understanding of the pharmacology of ﬂecainide so as toavoid drug-drug interactions. Patients on ﬂecainide, especially
elderly patients and in those with renal or hepatic insufﬁciency,
should be carefully monitored for adverse drug effects.
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